Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245833 | 0.87 | ATM (0.71) | HRH3ALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL14642155 | 0.86 | HRH3 (0.54) | HRH3ALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL27760871 | 0.86 | LMNA (0.58) | HRH3ALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL2841801 | 0.85 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2POLBHTTKDM4E | |
| SCHEMBL321890 | 0.83 | HRH3 (0.78) | HRH3ALDH1A1SMN1; SMN2HTTATM | |
| SCHEMBL19002261 | 0.83 | POLB (0.73) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL14496362 | 0.83 | ALDH1A1 (0.49) | HRH3ALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL19002669 | 0.83 | SMN1; SMN2 (0.52) | HRH3ALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL19002668 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2HTTATMKDM4E | |
| SCHEMBL10226400 | 0.82 | ALDH1A1 (0.50) | HRH3ALDH1A1SMN1; SMN2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HRH3 3512/4885ALDH1A1 2765/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.